EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study

Yuki Katsuya, Tatsuya Yoshida, Atsuo Takashima, Kan Yonemori, Akihiro Ohba, Shu Yazaki, Shigehiro Yagishita, Hiroko Nakahama, Osamu Kobayashi, Masatoshi Yanagida, Yasuhiro Irino, Akinobu Hamada und 1 weitere

International Journal of Clinical Oncology · 2024

DOI: 10.1007/s10147-024-02470-x ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Yuki Katsuya und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1050045, Japan. ykatsuya@ncc.go.jp. Hauptthemen laut MEDLINE: COVID-19, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with cancer, particularly those undergoing chemotherapy, are at risk from the low immunogenicity of Coronavirus Disease 19 (COVID-19) vaccines.

Methods

This prospective study assessed the seroconversion rate of COVID-19 vaccines among patients with cancer and hospital staff. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific IgG (S-IgG) concentrations were evaluated before the first vaccination, and 1–3 and 4–6 months after the second vaccination. The primary endpoint was the seroconversion rate measured 1–3 months after the second vaccine.

Results

In total, 590 patients and 183 healthy hospital staff were analyzed. At 1–3 months after the second vaccination, the S-IgG antibody concentration exceeded the cut-off value (20 BAU/mL) in 96.1% (567/590) of the patients with cancer and 100% (183/183) of the healthy controls ( p = 0.0024). At 4–6 months after the second vaccination, the S-IgG antibody concentration exceeded the cut-off value (20 BAU/ml for S-IgG) in 93.1% (461/495) of the patients with cancer and 100% (170/170) of the healthy controls ( p < 0.0001). Old age, being male, and low lymphocyte count were related to low SARS-CoV-2 S-IgG levels 1–3 months after the second vaccination among patients, while body mass index, smoking history, and serum albumin level were not. Patients undergoing platinum combination therapy and alkylating agent among cytotoxic drugs, and PARP inhibitor, mTOR inhibitor, and BCR-ABL inhibitor exhibited a low S-IgG antibody concentration compared to the no treatment group.

Conclusions

COVID-19 vaccine immunogenicity was reduced among patients with cancer, especially under several treatment regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19NeoplasmsFemaleHumansMaleAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GProspective StudiesSARS-CoV-2VaccinationAged

Stichwörter der Autor:innen

COVID-19 vaccineCancer patientsCancer treatmentsImmunogenicitySARS-CoV-2

Substanzen

Antibodies, ViralCOVID-19 VaccinesImmunoglobulin G

Autor:innen und Institutionen

  • Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1050045, Japan. ykatsuya@ncc.go.jp.
  • Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1050045, Japan.
  • Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1050045, Japan.
  • Department of Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1050045, Japan.
  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1050045, Japan.
  • Division of Molecular Pharmacology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1050045, Japan.

Zitieren

APA

Katsuya, Y., Yoshida, T., Takashima, A., Yonemori, K., Ohba, A., Yazaki, S., Yagishita, S., Nakahama, H., Kobayashi, O., Yanagida, M., Irino, Y., Hamada, A., & Yamamoto, N. (2024). Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02470-x

Vancouver

Katsuya Y, Yoshida T, Takashima A, Yonemori K, Ohba A, Yazaki S, et al. Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02470-x

BibTeX
@article{Katsuya2024,
  author = {Katsuya, Yuki and Yoshida, Tatsuya and Takashima, Atsuo and Yonemori, Kan and Ohba, Akihiro and Yazaki, Shu and Yagishita, Shigehiro and Nakahama, Hiroko and Kobayashi, Osamu and Yanagida, Masatoshi and Irino, Yasuhiro and Hamada, Akinobu and Yamamoto, Noboru},
  title = {Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1007/s10147-024-02470-x}
}
Kostenlos starten →